Kite registers new Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myeloma
Kite, A Gilead Company's iMMagine-6 trial joins a lineup of ongoing CAR T and PBC studies, most holding their prior status this week.
The week's most notable item is a newly registered Kite trial, with three other Gilead-related studies holding prior status.
- Kite, A Gilead Company registered a new Phase 3 trial, "iMMagine-6" (NCT07903506), comparing anitocabtagene autoleucel to autologous stem cell transplant in newly diagnosed multiple myeloma. The study is not yet recruiting, with an estimated start of February 2027.1 Planned enrollment is 750 participants.1 The primary endpoint is the rate of minimal residual disease-negative complete response or stringent complete response at 12 months.1
- Kite, A Gilead Company's Phase 1/2 trial of KITE-363 and KITE-753 in relapsed or refractory B-cell lymphoma, called PALISADES-1, remains active, not recruiting, with its last update posted on 2026-10-28.2 Recruitment remains open for frontline LBCL and r/r MCL in the KITE-753 Phase 1 a/b arm.2
- Gilead Sciences' Phase 2 trial combining seladelpar and cilofexor for primary biliary cholangitis remains recruiting, with its most recent update posted 2026-10-27.3 Planned enrollment is 132 participants.3
- Kite, A Gilead Company's Phase 3 trial comparing KITE-753 to axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma after first-line therapy remains active, not recruiting, with its last update posted 2026-10-26.4 Planned enrollment is 550 participants.4
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.